



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: **Antonio C. Wolff, MD**

Committee: **Oncologic Drugs Advisory Committee (ODAC)**

Meeting Date: **February 9, 2021**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: *Pembrolizumab for the treatment of patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery*, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/investments	(b) (6) a healthcare sector mutual fund	(b) (6)
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/s/
Signature

11 January 2021
Date